WHO ICTRP trial
The effect of Silymarin in type 2 diabetes.
IRCT20230318057749N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20230318057749N1 |
|---|---|
| Public title | The effect of Silymarin in type 2 diabetes. |
| Scientific title | The effect of Silymarin on the level of lipid profile and fasting blood sugar and HbA1c in patients with type 2 diabetes. |
| Primary sponsor | Islamic Azad University |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Type 2 Diabetic. Chapter IV Endocrine, nutritional and metabolic diseases(E00-E90);I Certain |
| Interventions | Intervention group: Silymarin supplement use -control group: Diet intake-Type 2 diabetes patients took Silymarin supplement in the form of 140 mg capsules from Gol Daru company - 3 times a day for 12 weeks.. |
| Registration date | Feb 24, 2024 |
| Target size | 60 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: